<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p35" style="overflow: hidden; position: relative; width: 935px; height: 1210px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_35{left:110px;top:1133px;letter-spacing:-0.1px;word-spacing:0.2px;}
#t2_35{left:459px;top:1133px;letter-spacing:0.3px;}
#t3_35{left:757px;top:1133px;word-spacing:-0.7px;}
#t4_35{left:220px;top:109px;letter-spacing:-0.1px;}
#t5_35{left:275px;top:131px;}
#t6_35{left:220px;top:153px;letter-spacing:-0.1px;}
#t7_35{left:220px;top:175px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t8_35{left:275px;top:197px;}
#t9_35{left:220px;top:220px;letter-spacing:-0.1px;word-spacing:0.1px;}
#ta_35{left:220px;top:242px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tb_35{left:275px;top:264px;letter-spacing:-0.1px;}
#tc_35{left:220px;top:286px;letter-spacing:-0.1px;}
#td_35{left:220px;top:308px;letter-spacing:-0.1px;}
#te_35{left:220px;top:330px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tf_35{left:220px;top:352px;letter-spacing:-0.1px;}
#tg_35{left:275px;top:375px;letter-spacing:-0.1px;}
#th_35{left:220px;top:397px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#ti_35{left:416px;top:397px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tj_35{left:220px;top:419px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tk_35{left:417px;top:419px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tl_35{left:220px;top:441px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tm_35{left:220px;top:463px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#tn_35{left:220px;top:485px;letter-spacing:-0.1px;word-spacing:-0.3px;}
#to_35{left:220px;top:507px;letter-spacing:-0.1px;}
#tp_35{left:220px;top:529px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tq_35{left:220px;top:552px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#tr_35{left:275px;top:574px;letter-spacing:-0.1px;word-spacing:-0.2px;}
#ts_35{left:220px;top:596px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tt_35{left:275px;top:618px;word-spacing:0.2px;}
#tu_35{left:220px;top:640px;letter-spacing:-0.1px;word-spacing:0.1px;}
#tv_35{left:275px;top:662px;}
#tw_35{left:220px;top:684px;letter-spacing:-0.1px;}
#tx_35{left:275px;top:706px;}
#ty_35{left:220px;top:729px;letter-spacing:-0.1px;}
#tz_35{left:275px;top:751px;}
#t10_35{left:220px;top:773px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t11_35{left:220px;top:795px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t12_35{left:275px;top:817px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t13_35{left:220px;top:839px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t14_35{left:220px;top:862px;letter-spacing:-0.1px;}
#t15_35{left:275px;top:884px;letter-spacing:-0.1px;word-spacing:0.2px;}
#t16_35{left:220px;top:906px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t17_35{left:275px;top:928px;}
#t18_35{left:220px;top:950px;letter-spacing:-0.1px;word-spacing:-0.1px;}
#t19_35{left:275px;top:972px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t1a_35{left:220px;top:994px;letter-spacing:-0.1px;}
#t1b_35{left:220px;top:1016px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t1c_35{left:220px;top:1039px;letter-spacing:-0.1px;word-spacing:0.1px;}
#t1d_35{left:220px;top:1061px;letter-spacing:-0.1px;word-spacing:-0.1px;}

.s1_35{
	FONT-SIZE: 67.5px;
	FONT-FAMILY: Calibri_f8x;
	color: rgb(0,0,0);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts35" type="text/css" >

@font-face {
	font-family: Calibri_f8x;
	src: url("fonts/Calibri_f8x.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg35Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg35" style="-webkit-user-select: none;"><object width="935" height="1210" data="35/35.svg" type="image/svg+xml" id="pdf35" style="width:935px; height:1210px; background-color:white; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_35" class="t s1_35">Medicare FFS Claims (Version K) Codebook</div>
<div id="t2_35" class="t s1_35">32</div>
<div id="t3_35" class="t s1_35">May 2017</div>
<div id="t4_35" class="t s1_35">0892 = Daclizumab, Parenteral, 25 mg (obsolete 1/01) (eligible for pass-through </div>
<div id="t5_35" class="t s1_35">payments) </div>
<div id="t6_35" class="t s1_35">0900 = Injection, Alglucerase per 10 units (eligible for pass-through payments) </div>
<div id="t7_35" class="t s1_35">0901 = Alpha I, Proteinase Inhibitor, Human per 10mg (eligible for pass-through </div>
<div id="t8_35" class="t s1_35">payments) </div>
<div id="t9_35" class="t s1_35">0902 = Botulinum Toxin, Type A per unit (eligible for pass-through payments) </div>
<div id="ta_35" class="t s1_35">0903 = CMV Immune Globulin (obsolete 12/00); Cytomegalovirus imm IV, vial (eligible </div>
<div id="tb_35" class="t s1_35">for pass-through payments) (eff. 1/01) </div>
<div id="tc_35" class="t s1_35">0905 = Immune Globulin per 500 mg (eligible for pass-through payments) </div>
<div id="td_35" class="t s1_35">0906 = RSV-ivig 50 mg (eligible for pass-through payments) </div>
<div id="te_35" class="t s1_35">0907 = Ganciclovir Sodium 500 mg injection (Not subject to national coinsurance) </div>
<div id="tf_35" class="t s1_35">0908 = Tetanus Immune Globulin, injection up to 250 units (Not subject to national </div>
<div id="tg_35" class="t s1_35">coinsurance) </div>
<div id="th_35" class="t s1_35">0909 = Interferon Beta - 1a </div>
<div id="ti_35" class="t s1_35">33 mcg (eligible for pass-through payments) </div>
<div id="tj_35" class="t s1_35">0910 = Interferon Beta - 1b </div>
<div id="tk_35" class="t s1_35">0.25 mg (eligible for pass-through payments) </div>
<div id="tl_35" class="t s1_35">0911 = Streptokinase per 250,000 iu (Not subject to national coinsurance) </div>
<div id="tm_35" class="t s1_35">0913 = Ganciclovir long act implant 4.5 mg (eligible for pass-through payments) </div>
<div id="tn_35" class="t s1_35">0914 = Reteplase, 37.6 mg (Not subject to national coinsurance) </div>
<div id="to_35" class="t s1_35">0915 = Alteplase injection,recombinant, 10mg (Not subject to national coinsurance) </div>
<div id="tp_35" class="t s1_35">0916 = Imiglucerase per unit (eligible for pass-through payments) </div>
<div id="tq_35" class="t s1_35">0917 = Dipyridamole, 10mg / Adenosine 6MG (Not subject to national coinsurance) </div>
<div id="tr_35" class="t s1_35">(obsolete 1/01) Pharmalogic stresses (eff. 1/01) </div>
<div id="ts_35" class="t s1_35">0918 = Brachytherapy Seeds, Any type, Each (eligible for pass-through payments) </div>
<div id="tt_35" class="t s1_35">(obsolete 4/01) </div>
<div id="tu_35" class="t s1_35">0925 = Factor VIII (Antihemophilic Factor, Human) per iu (eligible for pass-through </div>
<div id="tv_35" class="t s1_35">payments) </div>
<div id="tw_35" class="t s1_35">0926 = Factor VIII (Antihemophilic Factor, Porcine) per iu (eligible for pass-through </div>
<div id="tx_35" class="t s1_35">payments) </div>
<div id="ty_35" class="t s1_35">0927 = Factor VIII (Antihemophilic Factor, Recombinant) per iu (eligible for pass-through </div>
<div id="tz_35" class="t s1_35">payments) </div>
<div id="t10_35" class="t s1_35">0928 = Factor IX, Complex (eligible for pass-through payments) </div>
<div id="t11_35" class="t s1_35">0929 = Other Hemophilia Clotting Factors per iu (eligible for pass-through payments) </div>
<div id="t12_35" class="t s1_35">(obsolete 1/01) Anti-inhibitor per iu (eff. 1/01) </div>
<div id="t13_35" class="t s1_35">0930 = Antithrombin III (Human) per iu (eligible for pass-through payments) </div>
<div id="t14_35" class="t s1_35">0931 = Factor IX (Antihemophilic Factor, Purified, Non-Recombinant) (eligible for pass-</div>
<div id="t15_35" class="t s1_35">through payments) </div>
<div id="t16_35" class="t s1_35">0932 = Factor IX (Antihemophilic Factor, Recombinant) (eligible for pass-through </div>
<div id="t17_35" class="t s1_35">payments) </div>
<div id="t18_35" class="t s1_35">0949 = Plasma, Pooled Multiple Donor, Solvent/Detergent Treated, Frozen (not subject </div>
<div id="t19_35" class="t s1_35">to national coinsurance) </div>
<div id="t1a_35" class="t s1_35">0950 = Blood (Whole) For Transfusion (not subject to national coinsurance) </div>
<div id="t1b_35" class="t s1_35">0952 = Cryoprecipitate (not subject to national coinsurance) </div>
<div id="t1c_35" class="t s1_35">0953 = Fibrinogen Unit (not subject to national coinsurance) </div>
<div id="t1d_35" class="t s1_35">0954 = Leukocyte Poor Blood (not subject to national coinsurance) </div>

<!-- End text definitions -->


</div>
</body>
</html>
